Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,849,647 papers from all fields of science
Search
Sign In
Create Free Account
PR-01 steroid
Known as:
PR-01
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Monosaccharides
Steroids
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract PR-01: Systemic inhibition of receptor tyrosine kinase signaling by metformin
Brendan J. Quinn
,
M. Dallos
,
+5 authors
P. Dennis
Cancer Prevention Research
2012
Corpus ID: 75492573
Metformin is the most commonly prescribed drug for type II diabetes and is associated with decreased cancer risk. Previously, we…
Expand
2011
2011
Abstract PR-01: Properties of adenomas in subjects treated with difluoromethylornithine and sulindac for reduction of colorectal adenomas
P. Carpenter
,
Wen‐Pin Chen
,
C. McLaren
,
E. Gerner
,
F. Meyskens
2011
Corpus ID: 76610172
Difluoromethyl ornithine (DFMO), an ornithine decarboxylase inhibitor, and sulindac reduced the occurrence of colorectal adenomas…
Expand
2010
2010
Abstract PR-01: Inequalities in colorectal cancer screening uptake: Results from the first 2.6 million invitations in the organized screening program in the U.K
C. Wagner
,
G. Baio
,
+10 authors
J. Wardle
2010
Corpus ID: 71907898
Background: An organized, population-based colorectal cancer (CRC) screening program was initiated in England in 2006, offering…
Expand
2010
2010
Abstract PR-01: Vitamin D receptor expression is inversely associated with prostate cancer progression
Whitney K. Hendrickson
,
J. Kasperzyk
,
+9 authors
E. Giovannucci
2010
Corpus ID: 75671342
Background: Vitamin D is inversely associated with risk of several malignancies. Circulating vitamin D interacts with the vitamin…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE